Study guide
18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
Key Takeaways Explain This Topic AI
Antimicrobial stewardship in women's health prioritizes narrow-spectrum agents, shortest effective durations, and rigorous discrimination between asymptomatic colonization (which is left untreated in nonpregnant women) and active clinical infection.
Asymptomatic bacteriuria (ASB; ≥10⁵ CFU/mL) is universally screened and treated in pregnancy at 12–16 weeks gestation to prevent acute pyelonephritis, preterm labor, and low birth weight, whereas ASB in nonpregnant healthy women is never treated.
Beta-lactam antibiotics (penicillins and cephalosporins) and select macrolides (azithromycin, erythromycin base) possess extensive safety records across all three trimesters of pregnancy, maintaining first-line status.
Specific antimicrobials carry strict gestational timing contraindications: nitrofurantoin is contraindicated at term (38–42 weeks) due to neonatal hemolytic anemia risk, while trimethoprim-sulfamethoxazole (TMP-SMX) is avoided in the 1st trimester (folate antagonism/neural tube defects) and near term (neonatal kernicterus).
Fluoroquinolones (cartilage toxicity/arthropathy) and tetracyclines (permanent tooth discoloration/enamel hypoplasia after 16 weeks) are strictly avoided during pregnancy; in lactation, drug safety is assessed using the Relative Infant Dose (RID <10% generally compatible).
Last updated: October 2026
Principles of Antimicrobial Stewardship in Women's Health
Antimicrobial stewardship optimizes clinical outcomes while minimizing multidrug-resistant organisms (MDROs) and drug toxicities. Core tenets include prescribing the narrowest effective spectrum, utilizing cultures for de-escalation, and limiting therapy to the shortest effective duration.
Distinguishing Asymptomatic Colonization from Infection
Asymptomatic Bacteriuria (ASB): Isolation of ≥10⁵ CFU/mL of a single uropathogen in a clean-catch midstream urine specimen from an individual without lower urinary symptoms (dysuria, urgency, frequency) or systemic signs (fever, flank pain).
In Nonpregnant Women: In healthy nonpregnant females, ASB represents benign colonization. Treating ASB provides no clinical benefit, does not prevent cystitis, increases adverse effects, disrupts normal flora, and breeds resistance. IDSA guidelines strictly advise against screening or treating ASB in nonpregnant healthy women.
In Pregnant Women: In contrast, untreated ASB in pregnancy carries a 20% to 35% risk of progressing to acute maternal pyelonephritis , secondary to progesterone-mediated ureteral dilation, hydronephrosis, and mechanical compression by the gravid uterus. Pyelonephritis triggers maternal sepsis, ARDS, preterm labor, and low birth weight. ACOG and USPSTF mandate universal screening for ASB at the initial prenatal visit (12 to 16 weeks gestation) via urine culture, with prompt treatment (cephalexin, amoxicillin-clavulanate, or nitrofurantoin) and a test-of-cure urine culture 1 to 2 weeks post-treatment .
Vaginal Colonization: Incidental discovery of Candida , Gardnerella , or Actinomyces on routine Pap smears in asymptomatic patients represents benign colonization and must not be treated.
- Gestational Safety: First-Line Antimicrobial Classes
- 1. Penicillins
Mechanism & Safety: Bactericidal inhibition of bacterial cell wall peptidoglycan cross-linking via binding to penicillin-binding proteins (PBPs). Because mammalian cells lack peptidoglycan cell walls, beta-lactams have an exceptional therapeutic index and robust safety across all trimesters.
Clinical Formulations: Amoxicillin/ampicillin are safe for respiratory, enterococcal urinary, and Listeria monocytogenes infections (IV ampicillin). Penicillin G is first-line for intrapartum Group B Streptococcus (GBS) chemoprophylaxis (5 million units IV loading dose, then 2.5–3.0 million units IV every 4 hours until delivery). Benzathine penicillin G is the only proven curative therapy for syphilis ; allergic pregnant patients must undergo desensitization. Caution: Amoxicillin-clavulanate is strictly contraindicated in Preterm Premature Rupture of Membranes (PPROM) due to increased neonatal necrotizing enterocolitis (NEC).
2. Cephalosporins
Mechanism & Safety: Inhibition of cell wall synthesis (bactericidal) with first-line safety across all trimesters.
Clinical Formulations: First-generation cephalexin (500 mg PO BID-QID) is first-line for ASB and cystitis in pregnancy; cefazolin is gold standard for cesarean surgical prophylaxis. Second-generation agents (cefoxitin, cefotetan) provide anaerobic coverage for inpatient PID. Third-generation ceftriaxone (500 mg IM) is first-line for N. gonorrhoeae , while IV ceftriaxone treats inpatient antenatal pyelonephritis.
3. Macrolides
Mechanism & Safety: Reversibly binds the 50S ribosomal subunit, inhibiting protein synthesis. Oral azithromycin (1 g single dose) is first-line for Chlamydia trachomatis in pregnancy. Erythromycin base is safe for PPROM latency protocols. Cautions: Erythromycin estolate is contraindicated due to maternal drug-induced cholestatic jaundice. Clarithromycin is avoided due to animal teratogenicity data; azithromycin is preferred.
- Antimicrobials with Gestational Timing Restrictions
- 1. Nitrofurantoin (Macrobid)
Mechanism & Timing: Reduced by bacterial enzymes into reactive intermediates attacking ribosomes and DNA. Concentrates heavily in urine. Safe for cystitis and ASB in the 1st (when alternatives are lacking) and 2nd trimesters.
Contraindication at Term (38 to 42 Weeks) & Labor: Fetal/neonatal erythrocytes have immature glutathione reductase and low reduced glutathione (GSH). Exposure near delivery triggers acute neonatal hemolytic anemia , severe hyperbilirubinemia, and Heinz body formation.
2. Trimethoprim-Sulfamethoxazole (TMP-SMX, Bactrim)
Mechanism: Sequential dual inhibition of bacterial folic acid synthesis (trimethoprim inhibits dihydrofolate reductase; sulfamethoxazole inhibits dihydropteroate synthase).
First-Trimester Restriction (Weeks 1–12): Trimethoprim folate antagonism during organogenesis (weeks 3–8) increases risks of neural tube defects , cardiac malformations, and oral clefts.
Third-Trimester Near-Term Restriction (≥32–34 Weeks, Especially ≥36 Weeks): Sulfonamides competitively displace unconjugated bilirubin from albumin binding sites. In the newborn with an immature blood-brain barrier and deficient glucuronidation, displaced free bilirubin deposits in the basal ganglia, precipitating kernicterus (chronic bilirubin encephalopathy, choreoathetosis, sensorineural deafness).
Strictly Contraindicated Classes in Pregnancy
Antimicrobial Class Primary Representatives Gestational Safety Status Documented Toxicity & Fetopathic Mechanism
Fluoroquinolones Ciprofloxacin, Levofloxacin, Moxifloxacin Contraindicated across all trimesters High affinity for bone/cartilage. Juvenile animal studies demonstrate irreversible articular cartilage damage, erosive arthropathies, and permanent chondropathy in weight-bearing joints.
Tetracyclines Doxycycline, Minocycline, Tetracycline Contraindicated after 16 weeks gestation Readily cross placenta and chelate calcium orthophosphate. Causes permanent yellow-brown-gray tooth discoloration, enamel hypoplasia , and transient suppression of fetal long-bone growth; maternal acute fatty liver.
Aminoglycosides Gentamicin, Tobramycin, Amikacin Restricted / Avoided (Reserved for life-threatening sepsis) Accumulate in fetal perilymph and renal proximal tubules. Carries documented risks of fetal ototoxicity (8th cranial nerve damage, irreversible congenital sensorineural deafness) and fetal nephrotoxicity. Requires peak/trough monitoring.
Chloramphenicol Chloramphenicol Contraindicated throughout pregnancy and lactation Crosses placenta and human milk. Immature neonate cannot conjugate chloramphenicol, leading to Gray Baby Syndrome (cyanosis, hypothermia, flaccidity, cardiovascular collapse, and death).
Antimicrobial Pharmacotherapy During Lactation
Antimicrobial transfer into milk depends on molecular weight (<200 Da diffuses freely; >800 Da crosses poorly), protein binding (>90% bound leaves low free drug to enter milk), and milk pH (7.0–7.2 vs. plasma 7.4; weakly basic drugs undergo ion trapping).
Relative Infant Dose (RID): Quantitative metric assessing safety: RID = ( Infant dose via milk in mg/kg/day Maternal dose in mg/kg/day ) × 100 % \text{RID} = \left(\frac{\text{Infant dose via milk in mg/kg/day}}{\text{Maternal dose in mg/kg/day}}\right) \times 100\% RID = ( Maternal dose in mg/kg/day Infant dose via milk in mg/kg/day ) × 100%
An RID <10% is widely accepted as clinically safe in healthy term infants.
Class Guidance in Lactation
Penicillins & Cephalosporins: RID <1% to 2%. Fully compatible with breastfeeding; counsel mothers on potential mild infant loose stools or thrush.
Macrolides (Azithromycin, Erythromycin): Compatible with lactation (RID <5%).
Nitrofurantoin: Compatible in healthy term infants >1 month of age; avoid if infant is <1 month or has diagnosed Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency due to hemolysis risk.
TMP-SMX: Compatible in healthy term infants >2 months; avoid in premature infants, hyperbilirubinemic newborns, or infants with G6PD deficiency.
Fluoroquinolones: Low concentrations pass into milk; beta-lactams are preferred.
Chloramphenicol: Strictly contraindicated during lactation due to potential bone marrow suppression and Gray Baby Syndrome.